Evidence map›Paper›PMID 29910973›Full record

ArticleCurrent pathobiology reports2016

Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease.

Robert E Schwartz, Yaron Bram, Angela Frankel

Open access · bronzeAbstract read
In one paragraph

Article in Current pathobiology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Breaking the mold: 3D cell cultures reshaping the future of cancer research.Frontiers in cell and developmental biology · 2024
    Review
  3. Review
  4. Cell and Tissue Therapy for the Treatment of Chronic Liver Disease.Annual review of biomedical engineering · 2021
    Review
  5. Review
  6. Stem cell models as anThe Biochemical journal · 2019
    Review
  7. Review
  8. Review
  9. Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Robert E SchwartzWeill Cornell School of Medicine, New York, NY, USA.
Yaron BramWeill Cornell School of Medicine, New York, NY, USA.
Angela FrankelWeill Cornell School of Medicine, New York, NY, USA.
Cornell University · US

Funding

New Hepatocyte Model Systems to study Hepatitis B Virus InfectionK08DK101754 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2014 to 2018
$781k
Impact of species-specific host responses on restriction of hepatotropic virusesR21AI117213 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER, SCHWARTZ, ROBERT E · 2015 to 2016
$471k
NIAID NIH HHS R21 AI117213NIDDK NIH HHS K08 DK101754
6 · The paper itself

Abstract

purpose of reviewLiver disease is an important clinical and global problem and is the 16th leading cause of death worldwide and responsible for 1 million deaths worldwide each year. Infectious disease is a major cause of liver disease specifically and overall is even a greater cause of patient morbidity and mortality. Tools to study human liver disease and infectious disease have been lacking which has significantly hampered the study of liver disease generally and hepatotropic pathogens more specifically. Historically, hepatoma cell lines have been used for in vitro cell culture models to study infectious disease. Significant differences between human hepatoma cell lines and the human hepatocyte has hampered our understanding of hepatocyte pathogen infection and hepatocyte--pathogen interactions. RECENT

findingsDespite these limitations, great progress was made in the understanding of specific aspects of the life cycle of the canonical hepatocyte viral pathogen, Hepatitis C Virus. Over time various specific drugs targeting various proteins of the HCV virion or aspects of the HCV viral life cycle have been created that enable almost complete elimination of the virus in vitro and clinically. These drugs, direct-acting antivirals have enabled achieving sustained virologic response in over 90-95 percent of patients. SUMMARY: Despite the development of direct-acting antivirals and the extreme success in achieving sustained virologic response, there has only been limited success elucidating host-pathogen interactions largely due to the poor nature of the hepatoma platform. Alternative approaches are needed. Pluripotent stem cells are renewable, can be derived from a single donor and can be efficiently and reproducibly differentiated towards many cell types including ectodermal-, endodermal-, and mesodermal-derived lineages. The development of pluripotent stem cell-derived hepatocyte-like cells (iHLCS) changes the paradigm as robust cells with the phenotype and function of hepatocytes can be readily created on demand with a variety of genetic background or alterations. iHLCs are readily used as models to study human drug metabolism, human liver disease, and human hepatotropic infectious disease. In this review, we discuss the biology of the HCV virus, the use of iHLCs as models to study human liver disease, and review the current work on using iHLCs to study HCV infection.

Indexed as

Disease modelHepatitis C virusHepatotropic pathogenHuman hepatocyteInduced pluripotent stem CellsPluripotent stem cells

Identifiers

PMID29910973
PMCPMC5998817
OpenAlexW2498869952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.